Recently the U.S. Food and Drug Administration (FDA) issued warnings that Actos (pioglitazone), a drug to treat Type II Diabetes, may be linked to bladder cancer. The risk is even higher for those patients who take the medication at a higher dosage over an extended period of time according to The Wall Street Journal. Actos is one of several drugs that have contains pioglitazone.
Pioglitazone has been pulled from drug store shelves in France and Germany has recommended not prescribing medication containing pioglitazone to new patients after an epidemiological study by the Caisse National d’Assurance Maladie but it remains on drug store shelves here in the United States.
Takeda Pharmaceuticals, the manufacturer of Actos, has agreed to sponsor a study which looks at link between Actos and bladder cancer.
The FDA’s mid-review of a ten-year epidemiological study of 193,000 patients over the age of 40 with type II diabetes found that the patients who took Actos for more than 12 months had a 40 percent higher risk of developing bladder cancer.
Signs and symptoms of bladder cancer include blood in the urine which may or may not be visible to the eye or detected by microscopic investigation. Other symptoms include painful urination or urgency in urination.
The Farber Law Group, a personal injury law firm in Western Washington, is currently representing people who have bladder cancer and have taken Actos. Fill out our Contact Form if you would like more information.
Diabetes drug, Actos, recalled in the French market
Contact The Farber Law Group at 1-800-244-9087 or email@example.com to schedule a free and confidential case evaluation. We have offices in Seattle and Bellevue to assist you.